Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move. The stock action follows a corporate update earlier this week outlining progress in the company’s Phase 3 FLAMINGO-01 clinical trial and broader efforts to reduce…
Continue reading...